Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
0
Best Growth Stocks to Buy for January 16th
https://www.zacks.com/commentary/2210722/best-growth-stocks-to-buy-for-january-16th?cid=CS-ZC-FT-zacks_1_rank_additions|growth_additions-2210722
Jan 16, 2024 - NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.
0
Novo Nordisk (NVO) Upgraded to Strong Buy: What Does It Mean for the Stock?
https://www.zacks.com/stock/news/2212339/novo-nordisk-nvo-upgraded-to-strong-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2212339
Jan 18, 2024 - Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
0
MAIA Soars 20% on Interim Results From Lung Cancer Study
https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386
Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
0
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2212144/why-novo-nordisk-nvo-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2212144
Jan 18, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Best Growth Stocks to Buy for January 19th
https://www.zacks.com/commentary/2211318/best-growth-stocks-to-buy-for-january-19th?cid=CS-ZC-FT-zacks_1_rank_additions|growth_additions-2211318
Jan 19, 2024 - ARCO, NVO and ENS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2024.
0
TransCode (RNAZ) Down 50% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213010
Jan 19, 2024 - TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
0
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213712
Jan 22, 2024 - Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0
What are the Major Stock Market Risks for 2024?
https://www.zacks.com/commentary/2216190/what-are-the-major-stock-market-risks-for-2024?cid=CS-ZC-FT-spoken_word-2216190
Jan 25, 2024 - After Davos is over, let's prognosticate from the cheap seats.
0